Video

Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC

Author(s):

Tanios S. Bekaii-Saab, MD, FACP

Dr. Bekaii-Saab shares the approach his practice takes to essential biomarker testing and next-generation sequencing in order to improve patient outcomes.

Related Videos
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Related Content
Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Nataliya Uboha, MD, PhD, of Wisconsin School of Medicine
October 28th 2024

The Debate Over the Predictive Utility of PD-L1–Low Expression is Ongoing in ESCC

FDA accepts rivoceranib/camrelizumab NDA for HCC, acalabrutinib triplet yields 100% ORR in untreated mantle cell lymphoma, and more from OncLive this week.
October 26th 2024

The OncFive: Top Oncology Articles for the Week of 10/20